



Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

November 18, 2021

MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 18, 2021--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021.

Interested parties may access the pre-recorded and archived webcast of the presentation for 90 days following the conference through the "Events" section of Personalis' website at <http://investors.personalis.com>.

About Personalis

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The [Personalis NeXT Platform](#)® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis' [Clinical Laboratory](#) was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit www.personalis.com and follow Personalis on [LinkedIn](#) and [Twitter](#).

Forward-Looking Statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform or the Personalis Clinical Laboratory, Personalis' leadership, future sequencing for the VA Million Veteran Program, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis' filings with the U.S. Securities and Exchange Commission, including Personalis' most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors." Personalis disclaims any obligation to update such forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211118006333/en/): <https://www.businesswire.com/news/home/20211118006333/en/>

Investor Relations Contact:

Caroline Corner
investors@personalis.com
415-202-5678

Media Contact:

Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

Source: Personalis, Inc.